Objective: To evaluate the rate of remission of metabolic syndrome (Met Syn) among patients undergoing a brief, low-calorie lifestyle change weight loss intervention and to compare the baseline characteristics of patients who were remitted and not remitted from Met Syn at post-treatment. Research Methods and Procedures: Obese adults (N ¼ 36) meeting criteria for Met Syn enrolled in an outpatient fee-forservice behavioral weight loss intervention. Participants were assessed on key Met Syn variables (waist circumference, blood pressure, triglycerides, high-density lipoprotein (HDL) cholesterol and fasting blood glucose) at pre-and post-treatment. Results: The majority of patients (61%) responded to treatment after a 9.9% mean weight loss. Although Met Syn responders did not differ significantly from Met Syn non-responders on any baseline Met Syn criterion variable, responders had significantly lower baseline body mass indices (BMI; kg/m 2 ) and met criteria for fewer baseline Met Syn variables. As expected, Met Syn responders, compared with Met Syn non-responders, had significantly lower post-treatment waist circumference, systolic and diastolic blood pressures, triglycerides and fasting blood glucose. Patient groups did not differ significantly on weight lost (kg or %), or on the proportion of patients losing X10% of initial body weight. Discussion: In a community population, Met Syn responds to weight loss through a low-calorie lifestyle intervention; for some patients, however, the recommended 10% weight loss may not be enough for Met Syn remission.
Introduction
Metabolic syndrome (Met Syn), as defined by the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP-ATP III), is a cluster of conditions including abdominal obesity, elevated triglycerides, elevated blood pressure and elevated fasting glucose. 1 Met Syn affects approximately 22% of adults in the United States, 2 and its prevalence increases with age, 2,3 body mass index (BMI; kg/m 2 ) 3 and waist circumference. 4 Met Syn is associated with coronary heart disease, myocardial infarction, stroke and diabetes. 5 The syndrome is associated with increased mortality, both all-cause and that associated with cardiovascular disease. 5 Although specific treatment of the relevant individual components of Met Syn is often required, weight loss is widely recommended as the first-line approach to its management. 1, 6 It is well established that even moderate (B10%) weight loss may produce substantial improvements in the individual components of Met Syn whether achieved through behavior modification, improved nutrition, increased physical activity, weight loss medication or bariatric surgery. 1, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Fewer studies, however, have reported the actual rates of remission of Met Syn among patients losing weight (that is, the percentage of patients who initially meet diagnostic criteria for Met Syn but who after weight loss have improved sufficiently to no longer qualify for the diagnosis). It has been argued that the individual components should be addressed without regard to whether diagnostic criteria for the syndrome have been met. 16 Given that Met Syn is recognized in most quarters as a clinically important and risk-related entity with specific diagnostic criteria, and its growing prevalence among adults and children is noted with concern in epidemiological studies, the reduction in the numbers of patients who meet the threshold for diagnosis seems an important outcome. 3, 17 Among overweight and obese subjects with impaired glucose tolerance in the Diabetes Prevention Program, remission rates of Met Syn at year 3 were 38, 23 and 18% for the lifestyle modification, metformin and placebo groups respectively; the lifestyle change program produced an average weight loss of 7% after the initial 6 months. 10 (Of patients who originally did not meet criteria for Met Syn, 38, 47, and 53% of lifestyle, metformin and placebo subjects, respectively, acquired the diagnosis by year 3). In a 12-month trial of rimonabant for weight loss among overweight and obese patients with dyslipidemia, the prevalence of Met Syn fell from 53 to 26% in the group treated with rimonabant 20 mg, compared with a change from 52 to 41% in the placebo group; because these post-treatment figures include new cases that developed over the trial, actual remission rates cannot be determined from the report. 11 Finally, among patients undergoing weight loss surgery, rates of resolution of Met Syn as high as 95% have been reported. 18, 19 The studies noted earlier reported results on remission rates of Met Syn in weight loss interventions by examining very intensive research protocols, pharmacotherapy weight loss clinical trials or weight loss surgery. In the current study, we examined remission rates of Met Syn among obese adults enrolled in a relatively brief, moderate-intensity, fee-forservice low-calorie lifestyle change weight loss intervention. Further, Met Syn responders (those who no longer met criteria for Met Syn at post-treatment) and Met Syn non-responders (those who continued to meet criteria at post-treatment) were compared on weight loss, severity of symptoms at baseline and at treatment end, and degree of change in symptom severity. We hypothesized that (1) most Met Syn patients in this clinical weight loss program would remit with completion of the program, that is, no longer qualify for the diagnosis; (2) Met Syn responders, in comparison to non-responders, would lose a greater percentage of their baseline weight and (3) Met Syn responders, relative to non-responders, would have less severe Met Syn symptoms at baseline and post-treatment and greater improvement over treatment.
Methods

Participants and selection
We examined archival data from 178 participants enrolled in a 15-week fee-for-service, individually delivered, partial meal replacement low-calorie diet (MR-LCD) lifestyle change program (Focus Program) at the Weight Management Center of the Medical University of South Carolina. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research.
Data represent those patients who enrolled in the first 2 years in which this particular program was offered (2002) (2003) (2004) . Participant data were included if: (1) . Throughout the 15-week program, participants were expected to engage in daily self-monitoring of dietary intake, weight (including graphing) and exercise (pedometers). Weekly clinic visits were with a registered dietitian, exercise physiologist or psychology staff according to the treatment protocol. Visits were brief (15-30 min) and included review of dietary and exercise records, behavioral goal attainment, review of specific lifestyle change topics and setting of behavioral goals for the coming week.
Assessment
Weight loss was computed as the difference between the participants' baseline weight (week 1) and weight at last week of attendance. Waist circumference was measured with the patient standing; a Gulick II tape was placed in a horizontal plane at the level of the iliac crest without compressing the skin. Blood pressure was taken with the right arm with a correctly fitted cuff after the patient sat quietly for 5 min. A wall-mounted mercury sphygmomanometer was used. Fasting blood samples were drawn for measurements including triglyceride, HDL cholesterol and blood glucose levels, and were processed by the Medical University of South Carolina Laboratory Services. Categorization of participants as Met Syn responders or non-responders was determined by post-treatment assessment of Met Syn criteria. Baseline data were obtained within 2 weeks prior to treatment initiation and post-treatment samples were obtained approximately 2 weeks prior to the final visit.
Data analyses
Descriptive analyses were used to compute mean weight loss (kg), mean percentage weight loss and Met Syn response to treatment. Analysis of variance and w 2 analyses were used to compare baseline characteristics of Met Syn patients who completed treatment to those who did not, and to compare weight loss and pre-and post-treatment variables of responders to non-responders. Responder and non-responder comparisons involving waist circumference and HDL cholesterol were conducted separately by gender, to reflect gender-based Met Syn diagnostic criteria for these variables. Logistic regression was used to examine the relationship between percentage of weight lost and Met Syn remission status.
Results
Participant characteristics
Met Syn-positive patients (n ¼ 36) were primarily women (80.6%) and Caucasian (77.8%), consistent with our overall patient population; the mean age was 53.0±9.8 years.
Additional baseline variables are shown in Table 1 Table 2 . At treatment completion, 22 participants (61.1%) no longer met criteria for Met Syn and were considered responders. (The incidence of new cases of Met Syn was low. Of the 71 patients who completed treatment and did not meet criteria for Met Syn at baseline, seven patients (9.9%) developed Met Syn during treatment.) There was no difference in the proportion of men and women who responded (57.1 vs 62.1%, respectively; w 2 (1) ¼ 0.1, P40.05). Table 3 shows the percentage of participants who met each NCEP-ATP-III criterion at baseline and post-treatment by response status.
Comparisons of weight loss between Met Syn responders (total n ¼ 22; women ¼ 18) and Met Syn non-responders (total n ¼ 14; women ¼ 11) included gender as an independent variable to test for an interaction between response status and gender on weight loss (kg). Groups did not differ in lost weight (responders ¼ 9.7±4.9 kg loss, non-responders ¼ 11.8±6.8 kg loss; F (1,32) ¼ 1.7, P ¼ 0.20), but there was a main effect for gender (men ¼ 17.2 ± 3.8 kg loss, women ¼ 8.9 ± 4.9 kg loss; F (1,32) ¼ 17.2, Po0.001); the interaction between group and gender was not significant (P40.05).
No significant differences were found for percentage of weight loss (responders ¼ 10.4±4.8; non-responders ¼ 9.1±4.9, P ¼ 0.44), or the proportion of participants losing X10% of their baseline weight (responders ¼ 59.1%; nonresponders ¼ 42.9%, w Table 1 . No significant differences were found between groups for HDL cholesterol (P40.05) ( Table 1) .
Comparison of responders to non-responders: percentage change in Met Syn variables As expected, Met Syn responders, as compared with nonresponders, had significantly greater percentage changes in Abbreviations: BMI, body mass index; BP, blood pressure; HDL, high-density cholesterol. P a -value for the baseline group comparisons. P b -value for the posttreatment group comparisons. *P-values are for the group (responder vs non-responder) main effect; the interaction between group and gender was not statistically significant; italicized P-values are statistically significant at Po0.05. 
Discussion
Our primary hypothesis was that patients with Met Syn who undergo a brief low-calorie, partial meal replacement, behavioral fee-for-service weight loss program would experience remission of the syndrome according to accepted criteria. We found that 61% remitted by the end of the 15-week program in which all Met Syn patients completing the program achieved an average weight loss of 9.9% of baseline weight, regardless of remission status. Men and women were equally likely to remit, although men lost significantly more weight.
Few published reports have provided rates of remission of Met Syn in weight loss or other lifestyle change interventions. The present results, however, compare favorably to those from two large trials of non-surgical weight loss interventions. First, the Diabetes Prevention Program for overweight and obese participants with impaired glucose tolerance included a lifestyle change intervention arm, which induced a weight loss of about 7% over the first 6 months. Among participants who initially met criteria for Met Syn, those in the lifestyle change intervention demonstrated a remission rate of less than 10% after the first year and 38% at 3 years. That group's results were superior to those of the placebo/standard care condition, which showed a negligible weight loss and achieved remission rates of only 18% at 3 years. 10 Second, in a large 12-month weight loss trial of rimonabant among dyslipidemic patients, those on 20 mg rimonabant lost 9.3% of weight from screening; the prevalence of Met Syn in this group dropped from 53 to 26%, although the 12-month prevalence included an unreported number of patients who developed Met Syn during the trial. 11 Further, in a single-site study comparing 1-year treatment with lifestyle modification with and without sibutramine, sibutramine alone and sibutramine plus brief therapy, remission rates of 62, 72, 37 and 15% were reported, respectively. 
Remission of metabolic syndrome JD Lundgren et al
In contrast to our second hypothesis, the 10.4% weight loss of the responders did not differ significantly from the 9.1% weight loss of the non-responders. Although there was no statistically significant difference between groups on the percentage of subjects losing at least 10% of their baseline weight, our small sample size does not permit a definitive assessment of whether that degree of loss is a threshold level for resolution of Met Syn. A sizeable minority (40%) of responders lost less than that amount, but the trend was toward greater likelihood of remission among subjects losing at least 10% (68%) than among those losing less (47%). It remains plausible that achieving a weight loss of at least 10% of baseline body weight does put one at an advantage for Met Syn improvement, but that particular level of loss appears neither necessary nor sufficient. The weight loss target of 7-10% recommended for management of Met Syn should be considered an initial, but not necessarily ultimate, goal. 6 It is noteworthy that responders were significantly less obese at baseline than were non-responders (BMIs of 41.1 and 34.7 kg/m 2 , respectively). This suggests that a greater degree of weight loss may be necessary for more obese patients to achieve resolution of Met Syn. Further, adjunctive treatment (for example, pharmacotherapy) of specific Met Syn components may be needed in addition to behavioral weight loss for some patients, especially those with a higher BMI.
Our third hypothesis, that responders would have less severe Met Syn symptoms at baseline and post-treatment, was partially supported. Responders met fewer Met Syn criteria than did non-responders at both baseline and post-treatment. On the individual criterion at baseline, differences approached significance on waist circumference, fasting blood glucose and diastolic blood pressure, with responders having lower values than non-responders. Further, although not statistically significant, a similar, though less pronounced, trend toward more favorable values was observed on triglycerides, HDL cholesterol and systolic blood pressure. Given the small sample size, the failure to find significance on these individual variables may reflect power limitations.
As expected from the observed remission rates in the current study, we found several statistically significant differences between responders and non-responders on post-treatment Met Syn criterion values, including waist circumference, systolic blood pressure, diastolic blood pressure, fasting glucose and triglycerides. Similarly, Met Syn responders in comparison with non-responders showed a greater percentage change on triglycerides, systolic blood pressure and diastolic blood pressure.
It is noteworthy that the responders showed a nonsignificant trend toward unfavorable change (decrease) in HDL cholesterol despite the group's reduction in the prevalence of Met Syn, which includes a criterion of HDL below a genderspecific threshold. However, decreases in HDL with lower fat weight loss diets have been reported earlier. [21] [22] [23] [24] Reductions in HDL varied from 2 to 13% in these low-fat diet studies and about 10% reduction for both male and female responders in the present study. It is perhaps unsurprising that patients with less severe Met Syn symptoms and lesser degrees of obesity would be more likely to remit from Met Syn with participation in a relatively brief, low-calorie weight loss program. However, these findings suggest that these clinically measured variables may be useful guides to realistic expectations for management efforts that, as recommended, begin with weight loss. It is worth remembering that the basic treatment program studied was only 15 weeks in duration. Our data do not address whether greater weight loss achieved over a longer time period and/or through a more aggressive diet would have led to Met Syn remission by more of the heavier patients. In a study of patients undergoing weight loss on a very low-calorie diet, significant improvements in individual Met Syn criteria were noted at 4 weeks after average weight loss of 6.5%, and significant additional incremental improvements were noted after average weight loss of 15.1% was achieved; however, the vast majority of improvement occurred during the first 4-week period. 15 In two series of bariatric surgery patients with Met Syn (average BMIs 43-47 kg/m 2 ), remission rates of at least 95% were reported after weight losses of about 32-40%. 18, 19 Limitations of the present study include the relatively small sample size, paucity of men, over-representation of Caucasian individuals and lack of outcome data for patients who did not complete the program. There was no control group; it should be remembered, however, that the purpose was not to judge whether this weight loss program was an efficacious treatment for Met Syn, but rather to assess the extent of remission among patients completing a defined weight loss program. (Nonetheless, there is no reason to expect measurable remission of Met Syn within only 15 weeks among untreated subjects.) Also, we were unable to track any medication changes that may have occurred that would impact Met Syn variables. However, it is highly unlikely that initiation of medications for blood pressure, lipids or blood glucose control was responsible for remission of Met Syn in any meaningful number of cases, given the short duration of the program, the improvements in all components of Met Syn except HDL, and the fact that medications are not prescribed within the weight loss program. Also, although the purpose of this study was to examine remission rates immediately following a weight loss Remission of metabolic syndrome JD Lundgren et al program, it should be noted that we were not able to obtain long-term follow-up data on weight or Met Syn status.
Finally, it should be noted that several criteria sets for Met Syn have been proposed and modified since the study initiation. 16 As mentioned earlier, however, we chose to utilize the 2001 ATP III criteria because they constituted an accepted Met Syn definition at the time of patient enrollment. As such, these data should be interpreted cautiously and future studies using alternative Met Syn criteria are necessary to replicate these findings. In summary, we followed patients with Met Syn who completed a brief, low-calorie lifestyle change fee-for-service weight loss program partially based on meal replacements. With average weight losses of nearly 10% achieved over 15 weeks, 61.1% of these patients no longer met criteria for Met Syn. Less obese patients and those with less severe levels of Met Syn criteria were more likely to remit. Results suggest that weight loss obtained through such a moderately intensive program is an appropriate first approach for the management of Met Syn, though not necessarily sufficient in itself. Future studies should determine whether these results are replicable and enduring.
